Smith & Nephew
VC Fund
London, United Kingdom
Smith & Nephew is a VC fund in London focused on Medical Device and Medical. Smith & Nephew PLC designs, manufactures and markets orthopedic devices, sports medicine and ENT technologies, and wound-care solutions. Slightly more than 40% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is a sports medicine and ENT. The remaining 27% of revenue is from the advanced wound therapysegment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Smith & Nephew invests in
Stages Smith & Nephew invests in
Countries Smith & Nephew invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $2.7M–$30M
Investment Focus
Industry
- Medical Device 4 (80%)
- Medical 3 (60%)
- Health Care 3 (60%)
- Biotechnology 3 (60%)
- Manufacturing 2 (40%)
Stage
- Series B 2 (40%)
- Series C 1 (20%)
- Funding Round 1 (20%)
Country
- United States 2 (40%)
- Israel 1 (20%)
- United Kingdom 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Elga Lohler
Chief Human Resources Officer
|
Chief Human Resources Officer | Total investments: 0 | Find email | |
Jyothi Hartley
HR Global Category Lead, Indirect Procurement
|
HR Global Category Lead, Indirect Procurement | Total investments: 0 | Find email | |
Namal Nawana
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email | |
Nasreen Jacobson
Senior Director R&D Fort Worth
|
Senior Director R&D Fort Worth | Total investments: 0 | Find email | |
Richard DeSchutter
Lead Director
|
Lead Director | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Miach Orthopaedics
|
Miach Orthopaedics is a medical device company that develops bio-engineered surgical implants to facilitate new tissue growth. The company's product is the Bridge-Enhanced ACL Repair technology as a viable alternative to conventional ACL reconstruction for patients who have withstand an anterior cruciate ligament injury.Miach Orthopaedicswas founded on 2016 and is headquartered in Westborough, Massachusetts. | $30M / Series B / Jan 25, 2023 | |
Trice Medical
|
Trice Medical is founded to fundamentally improve orthopedic diagnostics for the patient, physician, and payor by providing instant, eyes-on, answers. Trice has pioneered fully integrated camera-enabled technologies that provide a clinical solution that is optimized for the physician's office. Their mission is to provide more immediate anddefinitive patient care, eliminating the false reads associated with current indirect modalities and significantly reducing the overall cost to the healthcare system.Trice Medical was founded in 2011 and is based in Pennsylvania. | Series C / Jan 14, 2019 | |
OrthoSpace
|
OrthoSpace develops and commercializes simple-to-implant, biodegradable balloon systems for the orthopaedic market. The company aims to create effective solutions for orthopaedics that reduce pain and increase patients’ range of motion while preserving patient bone and joint structures.The company’s first product has the CE mark and iscurrently marketed in Europe. InSpace™ is indicated for patients who suffer from rotator cuff injury, reducing shoulder pain and improving range of motion. | $7M / Dec 01, 2016 | |
|
OrthoSpace
|
OrthoSpace develops and commercializes simple-to-implant, biodegradable balloon systems for the orthopaedic market. The company aims to create effective solutions for orthopaedics that reduce pain and increase patients’ range of motion while preserving patient bone and joint structures.The company’s first product has the CE mark and iscurrently marketed in Europe. InSpace™ is indicated for patients who suffer from rotator cuff injury, reducing shoulder pain and improving range of motion. | $8M / May 19, 2015 | |
Michelson Diagnostics
|
Michelson Diagnostics is the developer and manufacturer of products based on Multi-Beam Optical Coherence Tomography (OCT), the uniquely powerful, innovative optical imaging technology that is capable of imaging living tissue microstructure at < 10 µm resolution,in real time, to depths of 1 mm or more. | $2.7M / Series B / Feb 16, 2015 |
Co-Investors
HealthpointCapital
2 deals together
Triventures
2 deals together
Amzak Health Investors
1 deal together
BioStar Capital
1 deal together
Charter Capital Partners
1 deal together
DSM Venturing
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Smith & Nephew invest in?
Smith & Nephew invests primarily in Medical Device, Medical and Health Care startups, most often at Series B and Series C stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Smith & Nephew's check size?
Smith & Nephew typically joins rounds of $2.7M–$30M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Smith & Nephew participates in.
How do I contact Smith & Nephew?
Public channels for Smith & Nephew include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Smith & Nephew?
The team at Smith & Nephew includes Elga Lohler (Chief Human Resources Officer), Jyothi Hartley (HR Global Category Lead, Indirect Procurement) and Namal Nawana (Chief Executive Officer), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
